A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

Summary Background In previous studies, etanercept significantly improved plaque psoriasis and was well tolerated. Objectives To examine further the efficacy and safety of etanercept and to assess maintenance of treatment effect after dose reduction of etanercept. Methods In this multicentre 24‐w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of dermatology (1951) 2005-06, Vol.152 (6), p.1304-1312
Hauptverfasser:	Papp, K.A., Tyring, S., Lahfa, M., Prinz, J., Griffiths, C.E.M., Nakanishi, A.M., Zitnik, R., Van De Kerkhof, P.C.M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Biological and medical sciences cytokine Dermatology Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Etanercept Female Humans Immunoglobulin G - administration & dosage Immunoglobulin G - therapeutic use Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - therapeutic use Injections, Subcutaneous Male Medical sciences Middle Aged phase III study psoriasis Psoriasis - drug therapy Psoriasis. Parapsoriasis. Lichen randomized controlled trial Receptors, Tumor Necrosis Factor - administration & dosage Receptors, Tumor Necrosis Factor - therapeutic use Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - therapeutic use Statistics as Topic tumour necrosis factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!